Analysts Set Liquidia Co. (NASDAQ:LQDA) PT at $24.00

Shares of Liquidia Co. (NASDAQ:LQDA) have been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $24.00.

Several research firms have issued reports on LQDA. BTIG Research lowered their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, August 19th. Bank of America cut their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Liquidia in a research note on Thursday, November 14th. Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Liquidia in a research report on Thursday, November 14th.

Liquidia Price Performance

LQDA stock opened at $11.42 on Friday. Liquidia has a 1-year low of $6.73 and a 1-year high of $16.99. The stock has a market capitalization of $966.59 million, a P/E ratio of -7.01 and a beta of 0.21. The business has a fifty day moving average price of $10.61 and a 200-day moving average price of $11.37.

Insider Activity at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 8,053 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $89,468.83. Following the sale, the chief executive officer now directly owns 812,193 shares of the company’s stock, valued at $9,023,464.23. This trade represents a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Russell Schundler sold 2,576 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $28,619.36. Following the completion of the transaction, the general counsel now directly owns 486,048 shares of the company’s stock, valued at approximately $5,399,993.28. This trade represents a 0.53 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,551 shares of company stock worth $236,021. 30.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Liquidia by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock valued at $42,587,000 after acquiring an additional 43,352 shares during the last quarter. Farallon Capital Management LLC purchased a new stake in shares of Liquidia in the first quarter worth about $30,311,000. Whitefort Capital Management LP boosted its stake in Liquidia by 119.8% during the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after buying an additional 927,546 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Liquidia by 144.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after buying an additional 230,820 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Liquidia by 18.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock worth $2,496,000 after acquiring an additional 32,076 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).